Antibiotic class with potent in vivo activity targeting lipopolysaccharide synthesis in Gram-negative bacteria.

Here, we describe the identification of an antibiotic class acting via LpxH, a clinically unexploited target in lipopolysaccharide synthesis. The lipopolysaccharide synthesis pathway is essential in most Gram-negative bacteria and there is no analogous pathway in humans. Based on a series of phenotypic screens, we identified a hit targeting this pathway that had activity on efflux-defective strains of

Déclaration de conflit d'intérêts

Competing interests statement:E.Z., D.A., V.R.K., S.L., G.O., P. Brandt, T.A.J., S.L.M., D.H., and A.K. have secured a patent [WO 2022/220725 (PCT/SE2022/050360)] for the compounds presented in this publication.